Vandalia Research, Inc. announced today that the United States Patent and Trademark Office granted U.S. Patent No. 8,163,489, covering Vandalia's process for large-scale DNA production using polymerase chain reaction (PCR).
The patent includes claims that cover Vandalia's system and process for conducting the PCR in a continuous reaction. This process allows Vandalia to scale PCR to multiple liters, allowing for large-scale production of DNA.
According to Derek Gregg, CEO, "This process is important in that it allows Vandalia to quickly and efficiently manufacture large amounts of DNA, including for use as linear expression cassettes, DNA vaccines, diagnostics, and other applications."
Vandalia Research is the first company to successfully scale-up the polymerase chain reaction (PCR) from an analytical tool to a viable large-scale manufacturing process, enabling DNA sequences to be made more efficiently and cost-effectively. Vandalia is helping companies develop vaccines, diagnostics, bio-agriculture, and gene therapies for existing and emerging markets, and is well-positioned as a key supplier for the research, clinical, and commercialization stages of these products.